Figure 6 : IYIY-I2-BODIPY mediated myeloid cells reduction is TrkC dependent.

From: Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy

Figure 6

4T1 tumor bearing mouse were randomly divided into four groups (saline, IYIY-I2-BODIPY, IYIY-I2-BODIPY + 10 μg/mouse isotype control IgG, IYIY-I2-BODIPY + 10 μg/mouse anti-TrkC blocking polyclonal antibodies). Compound, alone or in combination with antibodies as described was administrated into mice via tail vein, respectively. Mice were sacrificed 2 h after compounds administration. Percentages of (a) G-MDSCs and (b) neutrophils in spleen and TM were quantified using flow cytometry after cell surface staining. Data represent mean ± SEM of four mice. *p < 0.05 vs IYIY-I2-BODIPY was analyzed using student’s t-test.